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ABSTRACT 
Sitagliptin is a dipeptidyl peptidase 4-(DPP-4) inhibitor with glucose controlling capabilities that was effectively used for treating diabetes in 
the past. However, the oral administration of this drug caused such severe side effects that it was removed from the market.  Transdermal 
patches are innovative drug delivery systems and can be used for achieving efficient systemic effect by passing hepatic first pass metabolism 
and increasing the fraction absorbed. Transdermal patches of Sitagliptin phosphate (SIT) were prepared by the solvent casting evaporation 
technique using ethyl cellulose: HPMC, Eudragit RLPO, propylene glycol and permeation enhancer using different ratios. The physicochemical 
parameters such as flexibility, thickness, smoothness, weight variation, moisture content, hardness, folding endurance and te nsile strength 
were evaluated for the prepared patches. The formulation exhibited flexibility, uniform thickness and weight, smoothness, good drug content 
(95.65to 99.45%) and little moisture content. The in vitro diffusion studies were carried out using modified Franz diffusion cell using egg 
membrane as the diffusion membrane and the formulation followed the Higuchi diffusion mechanism. The formulation containing ethyl 
cellulose: HPMC as polymers showed faster release rate compared to Eudragit: HPMC.  The stability studies indicated that all the patches 
maintained good physicochemical properties and drug content after storing the patches in different storage conditions. Compatibility studies 
indicated that there was no interaction between the drug and polymers. Hence, the aim of the present study was to prepare the sustained 
release formulation (Transdermal patches) of the drug using different blend of polymers.  
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INTRODUCTION 
According to the Center for Disease Control, diabetes is the 
seventh leading cause of death in the United States and over 
29 million Americans currently have this disease, which 
translates to about 1 in every 11 people1. Two types of 
diabetes exist, including type 1 and type 2. Type 1 diabetes is 
usually present at birth and is caused by insulin deficiencies 
that prevent the pancreas from producing enough insulin. 
Patients with type 2 diabetes typically contract the disease 
over time. Type 2 diabetes is caused by insulin resistance 
and occurs when the pancreas produces insulin, though the 
body does not appropriately react to the protein2. Type 2 
diabetes increases one’s risk for many other health problems 
such as heart and blood vessel diseases, kidney damage, 
vision degeneration, nerve damage, and foot damage (even 
leading to amputation in some cases)3. Patients with type 2 
diabetes continuously alternate between a hyperglycaemic 
and hypoglycemic state, which refers to high blood glucose 
and low blood glucose levels, respectively4. It is imperative 
for these patients to monitor their blood glucose levels in 
order to remain in good health. Oral drug delivery and liquid 
injections are currently the two most common forms of 
diabetes treatment5. However, both methods implicitly 
present limitations. Patients who take oral anti-diabetic 
medications typically require high dosages in order for 
sufficient efficacy due to low bioavailability in drugs of this 
class. Patients also tend to experience negative side effects, 
such as vomiting and digestive pain from taking high-dose 
oral anti-diabetic medications. Patients who take 
hypodermic insulin injections are required to inject 
themselves with insulin up to three times a day; this method 
is very painful and inconvenient for patients who are 
dependent on this life-saving protein6.  A feasible treatment 
option for diabetes lays in transdermal drug delivery 
approaches.  It has been shown that the skin is a barrier that 
can be exploited for drugs to enter the body, so transdermal 
patch or cream formulation has potential for development as 
an alternative to the typical diabetes treatments. 
Furthermore, the use of transdermal patches can provide 
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sustained drug release over hours and even days. This novel 
methodology for diabetes treatment would have the ability 
to enable patients to lead quality lives without the pain from 
the numerous hypodermic insulin injections or the negative 
side effects caused by oral anti-diabetic medications7. 
However, this delivery method possesses limitations of its 
own, such as the necessity of selecting a drug small enough 
(with appropriate chemical properties) to facilitate 
transdermal diffusion8-11. SIT is a dipeptidyl peptidase-4 
(DPP-4) inhibitor. SIT works to competitively inhibit the 
enzyme dipeptidyl peptidase 4 (DPP-4). This enzyme breaks 
down the incretins GLP-1 and GIP, gastrointestinal hormones 
released in response to a meal. By preventing GLP-1 and GIP 
inactivation, they are able to increase the secretion of insulin 
and suppress the release of glucagon by the pancreas. This 
drives blood glucose levels towards normal12. The objective 
of present research was development of matrix type 
transdermal patches of SIT and to evaluate physicochemical, 
mechanical properties, in vitro drug release, in vitro 
permeation. 
MATERIAL AND METHODS 
Materials 
SIT was received from pharmaceutical company, as a gift 
sample. Propylene glycol, HPMC, ethyl cellulose and eudragit 
RLPO purchased from Himedia Laboratory, Mumbai. 
Methanol, chloroform purchased from CDH chemical Pvt. Ltd. 
New Delhi. Dialysis membrane of Mol Wt cutoff 1200 was 
purchased from Himedia Laboratory, Mumbai. All other 
chemicals and reagents used were of analytical reagent 
grade. 
Determination of λ max of SIT 
The λmax of SIT was determined by analyzing the drug 
solution in double beam ultraviolet spectrophotometer 
(Labindia-3000+). Accurately weighed 10 mg of drug was 
dissolved in 10 ml of 7.2 pH buffer solution in 10 ml of 
volumetric flask. The resulted solution was 1000µg/ml of 
strength and from this solution 1 ml solution was pipette out 
and transfer into 10 ml capacity of volumetric flask and 
volume was made upto 10 ml with 7.2 pH buffer solution. 
This solution was scan at wavelength 400-200 nm on UV 
spectrophotometer. The higher absorption peak was 
obtained at 260 nm which was the λmax of drug. 
Formulation of transdermal patches 
SIT containing transdermal patch was prepared utilizing 
method given by (Manvi et al., 2003)13 with slight 
modification.  The casting solution was prepared by 
dissolving weighed quantities of HPMC (825, 850 and 
875mg) and ethyl cellulose, Eudragit RLPO (125, 150 and 
175mg) in 10 ml of methanol and chloroform at mixture in 
ratio 1:1. To the resulting solution, 0.5% w/w of propylene 
glycol as plastisizer and 10% w/w penetration enhancer was 
added in this solution. Then drug (300 mg) was added and 
mixed thoroughly to form a homogeneous mixture. The 
casting solution was then poured into glass mould/petri dish 
specially designed to seize the contents. The glass mould 
containing the casting solution was dried at room 
temperature for 24 hours in vacuum oven. The patch was 
removed by peeling and cut into round shape of 2.5 X 2.5cm2. 
These patches were kept in desiccators for 2 days for further 
drying and enclose in aluminum foil and then packed in self-
sealing cover [Table 1]. 
 
Table 1 Formulation design of sitagliptin phosphate transdermal patches 
Formulation 
Code 
Drug 
(mg) 
HPMC 
(mg) 
Ethyl 
cellulose 
(mg) 
Eudragit 
RLPO 
(mg) 
Total 
polymer 
weight 
(mg) 
PEG 400 % 
w/w 
Chloroform: 
Methanol 
(1:1v/v) 
 
F1 300 875 125 - 700 1.0 10 
F2 300 850 150 - 700 1.0 10 
F3 300 825 175 - 700 1.0 10 
F4 300 875 - 125 700 1.0 10 
F5 300 850 - 150 700 1.0 10 
F6 300 825 - 175 700 1.0 10 
 
Dose calculations 
 Width of the plate (mould) = 5 cm 
 Length of the plate (mould) = 12 cm 
 No. of 2.5 x 2.5 cm  patch present whole(mould) = 12 
 Each film contains 25 mg of drug. 
 12 no. of films contains mg of drug? = 25×12 = 300mg 
 The amount of drug added in each plate was 
approximately equal to 300 mg. 
Characterization of transdermal patches 
The prepared transdermal patches were evaluated for the 
following parameters: 
Physical appearance 
All the transdermal patches were visually inspected for 
color, flexibility, homogeneity and smoothness. 
 
Film thickness 
The thickness of the patches was measured at five different 
places on a single patch of each formulation using a digital 
micrometer screw gauge and the mean values were 
calculated14. 
Weight variation 
A set of three patches from each batch were weighed on a 
digital balance and the mean values were calculated. The 
tests were performed on films which were dried at 60°C for 
4 h prior to testing14, 15. 
Drug content uniformity 
The patches (2.5*2.5 cm (Equivalent to 6.25 mg of drug) 
were taken into a three separate 10 ml volumetric flask and 
dissolved in methanol (10ml) with the help of mechanical 
shaker. The solution was centrifuged to separate out any 
particulate matter. 1ml of sample was withdrawn and 
transferred in volumetric flask (10 ml of capacity). The 
sample was dilute upto the mark with distilled water and 
analyzed by UV spectrophotometer at 260.0 nm using the 
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placebo patch solution as blank and the drug content was 
calculated14, 15. 
Folding endurance 
A strip of 2.5 cm × 2.5 cm was subjected to folding 
endurance by folding the patch at the same place repeatedly 
several times until a visible crack was observed and the 
values were reported16. 
Tensile strength 
The tensile strength of the patch was evaluated by using the 
tensiometer (Erection and instrumentation, Ahmedabad). It 
consists of two load cell grips. The lower one was fixed and 
upper one was movable. Film strips with dimensions of 
2×2cm were fixed between these cell grips, and force was 
gradually applied till the film broke. The tensile strength was 
taken directly from the dial reading in kg. 
                 ( )  
              (   )
                    (   )
 
Where, 
S = tensile stress in 980 dynes/cm2 
m = mass in grams 
g = acceleration due to gravity (980 dynes/cm2) 
b = breadth of strip in centimetres 
t = thickness of strip in centimetres 
Percent moisture content 
Weighed individually the films (1cm2) and kept them in 
desiccators containing calcium chloride at room 
temperature for at least 24 hrs. Film was weighed again; the 
difference in weight (initial and final weight) gives moisture 
content.        
                 
 
                         
            
     
Percent moisture uptake 
Weighed individually the films and kept them in desiccator 
containing calcium chloride at room temperature for at least 
24 hrs. remove the films from desiccators and exposed to 
4% relative humidity (Rh) using saturated solution of 
potassium chloride in a another desiccator until a constant 
weight is achieved. 
                 
 
                         
           
     
Compatibility studies 
In the present study, compatibility studies were carried out 
to assess any incompatibility between the drug and 
polymers. The IR studies were performed to check the 
compatibility with excipients. Spectra of the pure drug and 
the formulated patch were taken individually by the 
potassium bromide pellet method17.  
Stability studies  
The stability studies of the formulated transdermal patches 
were carried out on prepared films at different temperature 
and humidity: 25-30°C (60%RH) and 45-50°C (75%RH) over 
a period of 60 days. The patches were wrapped in aluminum 
foil and stored in a desiccator for stability study. The patches 
were characterized for drug content and other parameters at 
regular intervals (0, 15, 30, 45 and 60 days) 18. 
In Vitro skin permeation study 
The in vitro skin permeation study was carried out by using 
a Franz diffusion cell (receptor compartment capacity: 80 
ml: area: 2.5*2.5 cm (Equivalent to 6.25 mg of drug). The egg 
membrane was separated and used for in vitro study. The 
receiver compartment was filled with 40 ml of phosphate 
buffer, pH 7.4. The Transdermal patch was firmly pressed 
onto the centre of the egg membrane and then the 
membrane was mounted on the donor compartment. The 
donor compartment was then placed in position such that 
the surface of membrane just touches the receptor fluid 
surface. Heat is provided using a thermostatic hot plate with 
a magnetic stirrer. The receptor fluid is stirred by Teflon 
coated magnetic bead which is placed in the diffusion cell. 
The temperature of receptor compartment was maintained 
at 32±0.5ºC. The samples were withdrawn at different time 
intervals and analyzed for drug content 250 nm using UV-
visible spectrophotometer after suitable dilution with 
diluents19. At the same time receptor phase was replaced 
with an equal volume of buffer solution at each time interval.  
Kinetic study  
To know the mechanism of drug release from these 
formulations, the data were treated according to first order 
(log percentage of drug to be released vs time), Higuchi’s 
(percentage of drug released vs square root of time), and 
zero-order (percentage of drug released vs time) 
Korsmeyer-Peppas model (log percentage of drug to be 
released vs log time) patterns. 
RESULT AND DISCUSSION 
The λmax of the drug was found to be 260 nm. The 
calibration curve of the drug displayed a high linearity with 
an r2 value of 0.998 where a linear relationship was 
observed within the concentration range. All the patches 
prepared with different polymer concentration were found 
to be flexible, smooth, opaque, non-sticky and homogeneous 
in nature [Table 2]. This may be due to the presence of 
plasticizer. Marginal difference in thickness was observed 
among each group indicated that more the amount of 
polymer higher the thickness values [Table 4]. All the six 
patches have showed good folding endurance, and [Table 2] 
indicated that the patches have good flexibility. All the 
formulation show lowest moisture content i.e. less than 4%. 
Moisture in this value is required to provide strength and 
flexibility to the patches. In all formulations formulation F3 
contain minimum moisture contain 2.5±0.2and moisture 
uptake was less in F3 as compared to other formulation 
[Table 3]. The effect of concentration of polymers was 
observed on the percentage elongation and tensile strength. 
It was found that as the concentration of polymers 
increased, the percentage elongation and tensile strength 
were also increased within the patches. There was no 
significant difference in the drug content among the patches 
[Table 4] indicated content uniformity. The maximum drug 
content was found in formulation F3, 99.45±0.85%.
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Table 2 Physicochemical properties of the prepared transdermal patches 
F.  
Code 
Flexibility Smoothness Transparency Stickiness 
F1 Flexible Smooth Opaque Non-sticky 
F2 Flexible Smooth Opaque Non-sticky 
F3 Flexible Smooth Opaque Non-sticky 
F4 Flexible Smooth Opaque Non-sticky 
F5 Flexible Smooth Opaque Non-sticky 
F6 Flexible Smooth Opaque Non-sticky 
*Average of three determinations 
Table 3 % Moisture content and moisture uptake of different formulations 
S. No. F.Code % Moisture Content % Moisture Uptake 
1. F1 3.5±0.2 4.8±0.1 
2. F2 3.6±0.1 4.3±0.2 
3. F3 2.5±0.2 2.9±0.3 
4. F4 3.8±0.3 3.9±0.2 
5. F5 3.5±0.1 4.1±0.2 
6. F6 3.4±0.2 4.8±0.1 
*(n=3±SD) 
Table 4 Thicknesses folding endurance and drug content of different formulations 
S. No. Formulation Code Thickness 
(mm)* 
Folding Endurance* % Drug Content 
1. F1 145±5 156±5 98.85±0.45 
2. F2 148±6 189±6 95.65±0.65 
3. F3 150±4 192±4 99.45±0.85 
4. F4 154±5 173±5 97.85±0.45 
5. F5 152±2 130±2 98.98±0.65 
6. F6 154±4 125±3 96.65±0.74 
*(n=3±SD) 
In vitro drug release study of formulation was showed in 
[Table 5 and Fig. 1]. The release kinetics of the transdermal 
patches followed Higuchi diffusion mechanism [Table 6,7 
and Fig 2-5]. Stability studies showed that, there is no 
significant change in physical characteristics and drug 
content. Based on these results it was concluded that the 
formulated transdermal patches were found to be physically 
and chemically stable during the study period (60 days) 
. 
Table 5 In Vitro % permeation profile of sitagliptin in formulation F1-F6 
Time % of Drug Release 
(hr) F1 F2 F3 F4 F5 F6 
0.5 33.25 30.45 28.56 39.98 45.56 49.85 
1.0 45.58 40.23 35.65 48.89 52.45 55.65 
2.0 66.69 60.32 45.89 69.98 70.23 70.23 
4.0 78.89 72.23 55.89 82.23 85.56 89.98 
6.0 89.98 85.85 69.98 90.23 93.32 98.89 
8.0 98.89 90.45 75.56 99.23 99.45 99.69 
10.0 - 98.89 88.98 - - - 
12.0 - - 96.65 - - - 
 
 
Figure 1 In Vitro % permeation profile of sitagliptin in formulation F1-F6 
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Table 6 In Vitro Drug Release Data for optimized formulation F3 
Time 
(min) 
Square 
Root of 
Time 
Log Time 
Cumulative* 
Percentage Drug 
Release ± SD 
Log Cumulative 
Percentage Drug 
Release 
Cumulative 
Percent Drug 
Remaining 
Log cumulative 
Percent Drug 
Remaining 
0.5 0.707 -0.151 08.43±0.45 0.926 91.57 1.962 
1.0 1.000 0.000 16.53±0.23 1.218 83.47 1.922 
2.0 1.414 0.151 28.26±0.45 1.451 71.74 1.856 
4.0 1.732 0.239 35.68±0.65 1.552 64.32 1.808 
6.0 2.000 0.301 46.35±0.52 1.666 53.65 1.730 
8.0 2.236 0.349 54.23±0.47 1.734 45.77 1.661 
10.0 2.449 0.389 62.45±0.65 1.796 37.55 1.575 
12.0 2.828 0.452 69.38±0.32 1.841 30.62 1.486 
* Average of three determinations 
 
Figure2 Graph of zero order release kinetics 
 
Figure3 Graph of first order release kinetics 
 
Figure 4 Graph of Higuchi release kinetics 
 
Figure5 Graph of Peppas release kinetics 
 
Table 7 Kinetic data of Sitagliptin transdermal patches
Formulation code Regression coefficient   
Zero order First order Higuchi Peppas 
F3 0.981 0.903 0.992 0.989 
 
CONCLUSION 
The transdermal patches of SIT prepared by solvent casting 
method using a combination of ethylcellulose, eudragit, in 
various ratios of plasticizers and permeation enhancers were 
studied. All the formulations showed good physicochemical 
properties such as thickness, weight variation, drug content 
and folding endurance. The in vitro release data showed that 
drug release from the patch has been affected by the type 
and concentration of the polymer. From this data, optimized 
formulations were screened. Formulation F3 were 
considered as the best formulations. Based on the 
encouraging results, the SIT transdermal patch can be used 
as a controlled drug delivery system and frequency of 
administration can be minimized. Though the efforts were 
made for the development of SIT transdermal patch, long-
term pharmacokinetic and pharmacodynamic studies are 
needed to undertake the establishment of the usefulness of 
these patches. Further, these findings may help the industry 
to scale up for commercial production. Transdermal dosage 
form of SIT may provide clinicians an opportunity to offer 
more therapeutic options to their patients to optimize their 
care. 
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